Jiajing Cai1, Qi Qi1, Xuemeng Qian1, Jia Han1, Xinfang Zhu1, Qi Zhang2, Rong Xia3. 1. Department of Transfusion Medicine, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, People's Republic of China. 2. Department of Transfusion Medicine, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, People's Republic of China. friday0451@163.com. 3. Department of Transfusion Medicine, Huashan Hospital, Fudan University, 12 Urumqi Middle Road, Shanghai, 200040, People's Republic of China. xiarongcn@126.com.
Abstract
PURPOSE: During the past decades, PD-1/PD-L1 axis blockade has become a remarkable promising therapy which has exerted durable anti-tumor effect and long-term remissions on part of cancers. However, there are still some patients which do not show good response to the PD-1/PD-L1 targeted monotherapy. Till now, the widely accepted anti-tumor mechanism of PD-1/PD-L1 blockade is rejuvenating T cells, there is lack of studies which focus on other components of the tumor environment in the treatment of cancer with PD-1/PD-L1 blockade, especially the complicated relationship between macrophages and PD-1/PD-L1 pathway during the progression and treatment of cancer. METHODS: The relevant literatures from PubMed have been reviewed in this article. RESULTS: Even though the widely accepted anti-tumor mechanism of PD-1/PD-L1 blockade therapy is rejuvenating T cells, latest studies have demonstrated the complicated relationship between macrophages and PD-1/PD-L1 pathway during the progression and treatment of cancer and their engagement has serious implications for the therapeutic effect of PD-1/PD-L1 blockade agents. We focus on the dual regulation mechanisms between PD-1/PD-L1 axis and macrophages, and further clarify the mechanisms of resistance to PD-1/PD-L1 inhibitors related with macrophages. CONCLUSION: The combination of PD-1/PD-L1 blockade and macrophage-targeted therapy will exert synergetic anti-tumor effect and shape the future of cancer immunology and immunotherapy.
PURPOSE: During the past decades, PD-1/PD-L1 axis blockade has become a remarkable promising therapy which has exerted durable anti-tumor effect and long-term remissions on part of cancers. However, there are still some patients which do not show good response to the PD-1/PD-L1 targeted monotherapy. Till now, the widely accepted anti-tumor mechanism of PD-1/PD-L1 blockade is rejuvenating T cells, there is lack of studies which focus on other components of the tumor environment in the treatment of cancer with PD-1/PD-L1 blockade, especially the complicated relationship between macrophages and PD-1/PD-L1 pathway during the progression and treatment of cancer. METHODS: The relevant literatures from PubMed have been reviewed in this article. RESULTS: Even though the widely accepted anti-tumor mechanism of PD-1/PD-L1 blockade therapy is rejuvenating T cells, latest studies have demonstrated the complicated relationship between macrophages and PD-1/PD-L1 pathway during the progression and treatment of cancer and their engagement has serious implications for the therapeutic effect of PD-1/PD-L1 blockade agents. We focus on the dual regulation mechanisms between PD-1/PD-L1 axis and macrophages, and further clarify the mechanisms of resistance to PD-1/PD-L1 inhibitors related with macrophages. CONCLUSION: The combination of PD-1/PD-L1 blockade and macrophage-targeted therapy will exert synergetic anti-tumor effect and shape the future of cancer immunology and immunotherapy.
Entities:
Keywords:
Combination therapy; Macrophage; PD-1; PD-L1; T cell
Authors: Mahmoud S Hanafy; Stephanie Hufnagel; Andrea N Trementozzi; Wedad Sakran; Jeanne C Stachowiak; John J Koleng; Zhengrong Cui Journal: AAPS PharmSciTech Date: 2021-01-31 Impact factor: 3.246
Authors: Bin Lai; Jiwei Wang; Alexander Fagenson; Yu Sun; Jason Saredy; Yifan Lu; Gayani Nanayakkara; William Y Yang; Daohai Yu; Ying Shao; Charles Drummer; Candice Johnson; Fatma Saaoud; Ruijing Zhang; Qian Yang; Keman Xu; Kevin Mastascusa; Ramon Cueto; Hangfei Fu; Susu Wu; Lizhe Sun; Peiqian Zhu; Xuebin Qin; Jun Yu; Daping Fan; Ying H Shen; Jianxin Sun; Thomas Rogers; Eric T Choi; Hong Wang; Xiaofeng Yang Journal: Front Immunol Date: 2019-11-14 Impact factor: 7.561